scholarly journals Recent advances and SAR study of 2-substituted benzothiazole scaffold based potent chemotherapeutic agents

2021 ◽  
pp. 100258
Author(s):  
Kashif Haider ◽  
Neelima Shrivastava ◽  
Ankita Pathak ◽  
Rikeshwer Prasad Dewangan ◽  
Shaikh Yahya ◽  
...  
Keyword(s):  
Chemotherapeutic Agents ◽  
Recent Advances ◽  
Sar Study

The Role of Iron in Doxorubicin-Induced Cardiotoxicity: Recent Advances and Implication for Drug Delivery

2021 ◽  
Author(s):  
Yan Qin ◽  
Tao Guo ◽  
Zheng Wang ◽  
Yanjun Zhao
Keyword(s):  
Drug Delivery ◽  
Clinical Application ◽  
Chemotherapeutic Agents ◽  
Anthracycline Antibiotic ◽  
Recent Advances

As an anthracycline antibiotic, doxorubicin (DOX) is one of the most potent and widely used chemotherapeutic agents for treating various types of tumors. Unfortunately, clinical application of this drug results...

scholarly journals Recent advances in radiation therapy of pancreatic cancer

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1931 ◽  
Author(s):  
Bhanu Prasad Venkatesulu ◽  
Cheng-En Hsieh ◽  
Keith L Sanders ◽  
Sunil Krishnan
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Surgical Techniques ◽  
Chemotherapeutic Agents ◽  
Preoperative Chemoradiation ◽  
Survival Outcome ◽  
Recent Advances ◽  
Dismal Prognosis ◽  
Fraction Size

Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agents, radiation therapy (RT) techniques, and immunotherapy paradigms. RT dose, modality, fraction size, and sequencing are being evaluated actively, and the interplay between RT and immune effects has opened up newer avenues of research. In this review, we will emphasize recent advances in RT for pancreatic cancer, focusing on preoperative chemoradiation, RT dose escalation, sparing of the spleen to reduce lymphopenia, and combination of RT with immunotherapy.

Recent advances in the chemistry of iron-based chemotherapeutic agents

2020 ◽  
Vol 417 ◽  
pp. 213339 ◽  
Author(s):  
Uttara Basu ◽  
Mithun Roy ◽  
Akhil R. Chakravarty
Keyword(s):  
Chemotherapeutic Agents ◽  
Recent Advances ◽  
Iron Based

scholarly journals Recent advances in the regulation of cholangiocarcinoma growth

2010 ◽  
Vol 299 (1) ◽  
pp. G1-G9 ◽  
Author(s):  
Heather Francis ◽  
Gianfranco Alpini ◽  
Sharon DeMorrow
Keyword(s):  
Neoplastic Transformation ◽  
Therapeutic Strategies ◽  
Chemotherapeutic Agents ◽  
Biliary Epithelium ◽  
Recent Advances ◽  
Relative Rarity ◽  
Deadly Disease ◽  
Novel Therapeutic Strategies ◽  
Molecular Pathophysiology ◽  
Novel Therapeutic

Cholangiocarcinomas arise after the neoplastic transformation of the cholangiocytes that line the intra- and extrahepatic biliary epithelium. Symptoms usually do not present until late in the course of the disease, at which time they are relatively resistant to chemotherapeutic agents and as such are difficult to treat and display a poor prognosis. Because of the relative rarity of this disease, the overall volume of research into the molecular pathophysiology associated with this disease is small compared with other more prevalent tumors. However, the incidence of this devastating cancer is on the rise and renewed efforts to understand the pathogenesis of cholangiocarcinoma is needed to design novel therapeutic strategies to combat this disease. This review summarizes the recent advances into our knowledge and understanding of cholangiocarcinoma and highlights potential novel therapeutic strategies that may prove useful to treat this deadly disease.

Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances

2021 ◽  
pp. 174639
Author(s):  
Negar Bidar ◽  
Majid Darroudi ◽  
Ailin Ebrahimzadeh ◽  
Mohammadreza Safdari ◽  
Miguel de la Guardia ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Chemotherapeutic Agents ◽  
Recent Advances ◽  
Therapy And Diagnosis

Recent advances in the development of chemotherapeutic agents for malaria.

2020 ◽  
Vol 21 ◽  
Author(s):  
Neelima Shrivastava ◽  
Shah A. Khan ◽  
Saif Ahmad ◽  
Khalid Al Balushi ◽  
Asif Husain
Keyword(s):  
Antimalarial Drug ◽  
Hybrid Approach ◽  
Public Health Problem ◽  
Antimalarial Drugs ◽  
Chemotherapeutic Agents ◽  
World Health ◽  
Major Public Health Problem ◽  
Antimalarial Agents ◽  
Recent Advances ◽  
Made In

Introduction: Malaria, a devastating infectious parasitic disease, has been recognized by the World Health organization (WHO) as a major public health problem worldwide. It is one of the leading causes of morbidity and mortality in the developing countries. There are fewer number of the antimalarial drugs available in the market to combat this deadly disease. The situation is further worsened due to the emergence of resistant strains of Plasmodium falciparum, which warrants the search for novel antimalarial drugs capable of acting at multiple targets to expand the current antimalarial drug arsenal for better therapeutic outcome. Objectives: This review aimed to provide the reader with the recent advances and progress made in the development of chemotherapeutic agents for malaria. Methods: Literature review data on chemistry and antimalarial activity of natural and synthetic heterocyclic compounds published in the last ten years were compiled by referring various peer reviewed journal websites and medical search engines. Results and discussion: This review is covers the recent advances and progress made in the treatment strategies, patent granted, synthetic approaches, mechanism of action with more emphasis on structure activity relationship (SAR) of potential chemotherapeutic agents as antimalarial agents which could pave the way for the development of more effective and potent antimalarial agents. This review might interest the fellow researchers working on the development of novel antimalarial drug candidates with better therapeutic index. Conclusion: Based on the literature covered in the current review article and seeing the recent trends, authors are of the opinion that the multi target conjugated hybrid approach is the best strategy to discover and develop the effective antimalarial agents.

Nanotechnology Assisted Chemotherapy for Targeted Cancer Treatment: Recent Advances and Clinical Perspectives

2020 ◽  
Vol 20 (27) ◽  
pp. 2442-2458
Author(s):  
Huan-Rong Lan ◽  
Zhi-Qiang Wu ◽  
Li-Hua Zhang ◽  
Ke-Tao Jin ◽  
Shi-Bing Wang
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Chemotherapeutic Agents ◽  
Clinical Settings ◽  
Effective Parameters ◽  
Design And Synthesis ◽  
Recent Advances ◽  
Theranostic Agents ◽  
Reduced Toxicity ◽  
Encapsulation Methods

Nanotechnology has recently provided exciting platforms in the field of anticancer research with promising potentials for improving drug delivery efficacy and treatment outcomes. Nanoparticles (NPs) possess different advantages over the micro and bulk therapeutic agents, including their capability to carry high payloads of drugs, with prolonged half-life, reduced toxicity of the drugs, and increased targeting efficiency. The wide variety of nanovectors, coupled with different conjugation and encapsulation methods available for different theranostic agents provide promising opportunities to fine-tune the pharmacological properties of these agents for more effective cancer treatment methods. This review discusses applications of NPs-assisted chemotherapy in preclinical and clinical settings and recent advances in design and synthesis of different nanocarriers for chemotherapeutic agents. Moreover, physicochemical properties of different nanocarriers, their impacts on different tumor targeting strategies and effective parameters for efficient targeted drug delivery are discussed. Finally, the current approved NPs-assisted chemotherapeutic agents for clinical applications and under different phases of clinical trials are discussed.

Immunoliposomes: Synthesis, Structure, and their Potential as Drug Delivery Carriers

2020 ◽  
Vol 16 (4) ◽  
pp. 306-319 ◽  
Author(s):  
Divya Sandeep ◽  
Nour M. AlSawaftah ◽  
Ghaleb A. Husseini
Keyword(s):  
Drug Delivery ◽  
Cancer Treatment ◽  
Drug Targeting ◽  
Therapeutic Potential ◽  
Chemotherapeutic Agents ◽  
Recent Advances

Immunoliposomes have emerged as attractive drug targeting vehicles for cancer treatment. This review presents the recent advances in the design of immunoliposomes encapsulating a variety of chemotherapeutic agents. We provided an overview of different routes that can be used to conjugate antibodies to the surfaces of liposomes, as well as several examples of stimuliresponsive immunoliposome systems and their therapeutic potential for cancer treatment.

scholarly journals Recent Advances in Cancer Stem Cell-Targeted Immunotherapy

Cancers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 310 ◽  
Author(s):  
Narayanasamy Badrinath ◽  
So Yoo
Keyword(s):  
Residual Disease ◽  
Checkpoint Inhibitors ◽  
Chemotherapeutic Agents ◽  
Oncolytic Viruses ◽  
Complete Regression ◽  
Combination Therapies ◽  
Immune Markers ◽  
Recent Advances ◽  
Tumor Cell Heterogeneity ◽  
Recent Trends

Cancer stem cells (CSCs) are one of the reasons for the relapse of cancer cells and metastasis. They have drug resistance against most chemotherapeutic agents. CSCs are also responsible for tumor cell heterogeneity and cause minimal residual disease. In order to achieve complete regression of tumors, CSCs have to be targeted. Recent advances in immunotherapies have shown promising outcomes in curing cancer, which are also applicable to target CSCs. CSCs express immune markers and exhibit specific immune characteristics in various cancers, which can be used in immunotherapies to target CSCs in the tumor microenvironment. Recently, various strategies have been used to target CSCs. Adaptive T-cells, dendritic cell (DC)-based vaccines, oncolytic viruses, immune checkpoint inhibitors, and combination therapies are now being used to target CSCs. Here, we discuss the feasibility of these immunological approaches and the recent trends in immunotherapies to target CSCs.

Sign in / Sign up

Export Citation Format

Share Document